SIGA to Discuss Fourth Quarter and Year-End 2010 Results of Operations on March 9, 2011

NBC News Clone summarizes the latest on: Wbna41871220 - Breaking News | NBC News Clone. This article is rewritten and presented in a simplified tone for a better reader experience.

NEW YORK, March 2, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report fourth quarter and full-year 2010 results on Wednesday, March 9, 2011.

NEW YORK, March 2, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report fourth quarter and full-year 2010 results on Wednesday, March 9, 2011.

Management will host a conference call and simultaneous webcast to discuss the results of operations and provide an update on recent business developments at 4:30 P.M. ET on Wednesday, March 9, 2011. Participants should call (877) 564-1219 (United States/Canada) or (973) 638-3429 (International) and request the SIGA call or provide confirmation code 48896268. A live broadcast of the call will be available on the Company's website at under the 'Events & Presentations' tab in the Investor Relations section.

A replay of the call will be available approximately two hours after the call and will be accessible until 11:59 p.m. on Wednesday, March 16, 2011. To listen to the replay, dial (800) 642-1687 (Domestic) or (706) 645-9291 (International) and enter the code 48896268. The webcast of the event will also be archived on the Company's website for one year under the 'Events & Presentations' tab in the Investor Relations section.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

CONTACT: KCSA Strategic Communications Todd Fromer / Marybeth Csaby 212-896-1215 / 1236 Tfromer@kcsa.com / mcsaby@kcsa.com
×
AdBlock Detected!
Please disable it to support our content.

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone